BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3693868)

  • 1. Correlates of early neuroleptic response using a uniform haloperidol dose.
    Bowers MB; Swigar ME; Jatlow PI; Hoffman FJ; Goicoechea N
    Int Clin Psychopharmacol; 1987 Jul; 2(3):255-60. PubMed ID: 3693868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma catecholamine metabolites and early response to haloperidol.
    Bowers MB; Swigar ME; Jatlow PI; Goicoechea N
    J Clin Psychiatry; 1984 Jun; 45(6):248-51. PubMed ID: 6725216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma catecholamine metabolites and treatment response at neuroleptic steady state.
    Bowers MB; Swigar ME; Jatlow PI; Hoffman FJ
    Biol Psychiatry; 1989 Mar; 25(6):734-8. PubMed ID: 2923935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum haloperidol concentrations and clinical response in acute psychosis.
    Miller DD; Hershey LA; Duffy JP; Abernethy DR; Greenblatt DJ
    J Clin Psychopharmacol; 1984 Dec; 4(6):305-10. PubMed ID: 6511996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ratio of serum prolactin to haloperidol and early clinical outcome in acute psychosis.
    Swigar ME; Jatlow PI; Goicoechea N; Opsahl C; Bowers MB
    Am J Psychiatry; 1984 Oct; 141(10):1281-3. PubMed ID: 6486269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol.
    Brown AS; Gewirtz G; Harkavy-Friedman J; Cooper T; Brébion G; Amador XF; Malaspina D; Gorman JM
    Neuropsychopharmacology; 1997 Nov; 17(5):317-25. PubMed ID: 9348547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasma monitoring of haloperidol. Correlation with clinical efficacy and plasma prolactin levels].
    Giraud-Serio J; Goyot C; Debray Q; Plaisant O; Grenier J; Pélicier Y
    Ann Med Psychol (Paris); 1985 Nov; 143(9):900-11. PubMed ID: 3834819
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasma concentrations of haloperidol and prolactin and clinical outcome in acutely psychotic patients.
    Aschauer HN; Schönbeck G; Langer G; Koinig G; Resch F; Hatzinger R; Chaudry HR; Sieghart W
    Pharmacopsychiatry; 1988 Sep; 21(5):246-51. PubMed ID: 3227055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex differences in plasma homovanillic acid in acute psychosis.
    Bowers MB; Swigar ME; Jatlow PI
    N Engl J Med; 1983 Apr; 308(14):845-6. PubMed ID: 6835278
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasma haloperidol and clinical response: a role for reduced haloperidol in antipsychotic activity?
    Shostak M; Perel JM; Stiller RL; Wyman W; Curran S
    J Clin Psychopharmacol; 1987 Dec; 7(6):394-400. PubMed ID: 3429700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis.
    Mazure CM; Nelson JC; Jatlow PI; Bowers MB
    Biol Psychiatry; 1991 Sep; 30(5):475-82. PubMed ID: 1932395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent life stressors and biological markers in newly admitted psychotic patients.
    Mazure CM; Quinlan DM; Bowers MB
    Biol Psychiatry; 1997 Apr; 41(8):865-70. PubMed ID: 9099413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of route of administration on haloperidol plasma levels in psychotic patients.
    Bianchetti G; Zarifian E; Poirier-Littre MF; Morselli PL; Deniker P
    Int J Clin Pharmacol Ther Toxicol; 1980 Jul; 18(7):324-7. PubMed ID: 7429678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Haloperidol. Plasma monitoring and hormonal effects of treatment].
    Goyot C; Debray Q; Dugas M; Guay C; Giraud J; Grenier J
    Pathol Biol (Paris); 1985 Dec; 33(10):999-1004. PubMed ID: 2937009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of neuroleptic blood levels in the treatment of acute psychosis.
    Zohar J; Shemesh Z; Belmaker RH
    J Clin Psychiatry; 1986 Dec; 47(12):600-3. PubMed ID: 3782046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
    Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL
    Encephale; 1982; 8(1):1-8. PubMed ID: 7094868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early neuroleptic response in psychotic men and women: correlation with plasma HVA and MHPG.
    Bowers MB; Swigar ME; Jatlow PI; Hoffman F; Giocoechea N
    Compr Psychiatry; 1986; 27(3):181-5. PubMed ID: 2872015
    [No Abstract]   [Full Text] [Related]  

  • 18. Plasma drug and homovanillic acid levels in psychotic patients receiving neuroleptics.
    Harris PQ; Brown SJ; Friedman MJ; Bacopoulos NG
    Biol Psychiatry; 1984 Jun; 19(6):849-60. PubMed ID: 6146355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Standard and high doses of haloperidol. Clinical, pharmacokinetic and pharmacodynamic aspects].
    Schilkrut R; Haverbeck C; Duran E; Delgado S; Kohen P; Birkner R; Katz I
    Acta Psiquiatr Psicol Am Lat; 1981; 27(4-5):315-24. PubMed ID: 7348089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients.
    Ulrich S; Sandmann U; Genz A
    Pharmacopsychiatry; 2005 Jul; 38(4):171-7. PubMed ID: 16025420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.